Providing Rapid Diagnostics
to Guide Pediatric Treatment

Every child
deserves a chance to live their story

Rady Children’s Institute for Genomic Medicine® offers rapid and ultra-rapid whole genome sequencing to help physicians identify or rule out genetic diseases in one step. We empower clinicians to intervene quickly with precision care and make disease-specific treatment decisions to improve the lives of critically-ill babies, children and their families.

Rapid
Results

Our workflow is optimized for speed and accuracy. In medically urgent cases, preliminary results are returned in less than three days.

icon of doctors with speech bubbles

Clinical Consultation

Our clinical genomics experts are available to consult with ordering clinicians from patient selection to return of results. They also offer evidence-based insight on diagnosis-specific medical management options.

Exceptional Expertise

Our genomic specialists include research scientists, board certified medical geneticists, genetic counselors, neonatologists and pediatricians in various specialties.

Slide
Rylee
Rylee

Rapid Whole Genome Sequencing has truly been a game changer in the PICU and CVICU.

— Jason Knight, MD
Medical Director- PICU
CHOC Children’s Hospital of Orange County

Slide
Rylee
Rylee

The fact that I can send off a sample and get a result within a few days on a critically ill patient is just amazing to me.

— Jennifer Burton, MS, CGS
Clinical Genetic Counselor
Children’s Hospital of Illinois

next arrow
 
previous arrow
A precise rapid diagnosis can have a profound impact on patient outcomes.
The earlier rapid Whole Genome Sequencing™ is employed, the greater the potential patient benefit.

Why Choose Rady Children’s Institute for Genomic Medicine®?​

When a child is struggling to survive, our goal is to deliver rapid, robust phenotype-driven results in time to make a difference.

We offer clinically evaluated genome-wide testing with demonstrated utility for acute patient indications.

Along with a detailed molecular diagnostic clinical report, our lab and medical directors provide ordering clinicians with tele-mentoring to help guide patient care.

The entire RCIGM team is driven by a passion for optimizing rapid genomic testing to help medical teams at the bedside provide personalized life-changing treatment for the youngest, sickest patients.

We’ve partnered with the biggest names in genomic sequencing and data science, leveraging AI and a fanatical focus on process engineering, to deliver the fastest most accurate results.

We translate our research and innovation into clinical care. We collaborate with leading research organizations on studies that document the clinical and economic value of rWGS® in critical neonatal and pediatric care.

Our Clinical Genome Center is CAP accredited (#9487427) and CLIA certified (#05D12129627). We are licensed to provide clinical diagnostic testing in all 50 states.

Join Our Growing Rapid Precision Medicine™ Network

We provide clinical sequencing and clinical decision support to children’s hospitals across the US.

RCIGM also works with healthcare, medical research and life science alliances globally to expand access to whole genome sequencing for genetic disease. Learn more about our collaborations with organizations including the Vermont Oxford Network; the Sanford Children’s Genomic Medicine Consortium; and the Medical Genome Initiative.

Frequently Asked Questions

rWGS® is best considered for critically-ill infants and children in the inpatient setting for which a rapid genetic diagnosis could impact medical management and outcomes.

Indications for rWGS® testing include:

  • Critically-ill infants and children in the intensive care unit with no unifying diagnosis
  • Critically-ill infants and children for whom a rapid molecular diagnosis may inform medical management, treatment and/or prognosis
  • Molecular diagnosis of suspected genetic disease
    Identification of rare genetic disease variants in patients who have failed to receive a diagnosis despite extensive work-up and previous testing
  • Infants and children with a history of multiple hospitalizations or readmission within 30 days of discharge for an unexplained condition
  • Infants or children with prolonged hospital stay

Benign and Likely Benign variants are not reported. In addition, RCIGM-CGC does not offer reporting on carrier status, pharmacogenetic markers, polygenic risk scores, or genome wide association studies (GWAS) risk variants.

Talk with us

Whether you have questions or are ready to get started, our team is here to help. 

Lorem Ipsum Delores our Newsletter

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam dignissim posuere semper. Nunc et dapibus turpis, vitae pellentesque nisl.